```html

Quinine‑Induced Psychosis – A Patient‑Friendly Guide

Overview

Quinine is an alkaloid derived from the bark of the cinchona tree. Historically it was the primary treatment for malaria, but today it is most often encountered in low‑dose form as a prescription for nocturnal muscle cramps or, in some countries, as an ingredient in flavored “tonic” beverages. Although quinine is generally safe at therapeutic doses, it can cause a range of neuropsychiatric side effects, the most severe being quinine‑induced psychosis.

• What it is: A reversible, drug‑related psychotic disorder characterized by hallucinations, delusions, mood disturbances, and disorganized thinking that occurs after exposure to quinine.
• Who it affects: Adults of any age who take quinine, especially those using higher doses, taking it for prolonged periods, or who have pre‑existing psychiatric or neurological conditions.
• Prevalence: True incidence is hard to determine because cases are often under‑reported. Large pharmacovigilance databases (FDA Adverse Event Reporting System, 2023) list ≈ 0.02 % of quinine exposures as resulting in serious neuropsychiatric events, with psychosis representing a subset of those reports. The risk rises to about 0.1 % in patients receiving >300 mg/day for more than two weeks.<sup>1</sup>

Symptoms

Symptoms usually appear within days to weeks after starting quinine, but delayed onset (up to several months) has been described.

Psychotic features

• Hallucinations: Seeing, hearing, or feeling things that are not present. Visual (e.g., flashing lights) and auditory (e.g., voices) are most common.
• Delusions: Fixed false beliefs such as persecution (“people are trying to poison me”) or grandiosity (“I have special powers”).
• Paranoia: Unexplained fear that others intend harm.

Thought and behavior changes

• Disorganized speech or thinking (jumping from topic to topic).
• Agitation or extreme restlessness.
• Catatonic‑like muteness or stupor (rare).

Mood and affect

• Depression, anhedonia, or irritable mood.
• Manic‑like excitement or euphoria.

Other neurologic signs

• Headache, dizziness, or “brain fog.”
• Auditory or visual disturbances that are not full‑blown hallucinations (e.g., blurred vision, ringing in ears).
• Peripheral neuropathy or cinchonism (tinnitus, nausea, sweating) may accompany psychosis.

Temporal pattern

Symptoms improve within 2–7 days after stopping quinine in most patients, but some may take several weeks for full resolution, especially if high doses were used.

Causes and Risk Factors

Mechanism of toxicity

Quinine crosses the blood–brain barrier and interferes with neuronal voltage‑gated sodium channels and GABAergic transmission, leading to cortical hyperexcitability. It also promotes the release of dopamine, a neurotransmitter involved in psychotic states.<sup>2</sup>

Risk factors

• High daily dose: ≥200 mg for men, ≥150 mg for women, especially >300 mg/day.
• Prolonged therapy: >2 weeks of continuous use.
• Renal impairment: Decreased clearance raises plasma quinine levels.
• Concomitant CNS‑active drugs: Antidepressants, antipsychotics, or antiepileptics may potentiate toxicity.
• Pre‑existing psychiatric illness: Schizophrenia, bipolar disorder, or severe anxiety increase vulnerability.
• Genetic polymorphisms: Variants in CYP3A4/5 that slow quinine metabolism (still under investigation).
• Elderly patients: Age‑related decline in hepatic and renal function.

Diagnosis

Quinine‑induced psychosis is a diagnosis of exclusion; clinicians must first rule out primary psychiatric disorders, infectious encephalitis, metabolic derangements, and other drug‑induced psychoses.

History taking

• Detailed medication list (prescription, OTC, supplements, tonic drinks).
• Timing of symptom onset relative to quinine initiation or dose changes.
• Renal and hepatic function, recent infections, or substance use.

Physical & neurological exam

Look for signs of cinchonism (tinnitus, visual disturbances, nausea) that support quinine toxicity.

Laboratory tests

• Serum quinine level: Not routinely available but can confirm toxicity in academic centers.
• Basic metabolic panel: Electrolytes, glucose, renal function (creatinine, BUN).
• Liver function tests (AST, ALT, bilirubin).
• Complete blood count to exclude infection.

Imaging & other studies

• CT or MRI brain: Usually normal; performed to exclude structural lesions.
• EEG: May show diffuse slowing but is not specific.
• Urine toxicology: To rule out concomitant illicit drug use.

Diagnostic criteria (adapted from DSM‑5 for substance‑induced psychotic disorder)

1. Psychotic symptoms develop during or shortly after quinine exposure.
2. Symptoms cause clinically significant distress or impairment.
3. The disturbance is not better explained by a primary psychotic disorder, mood disorder, or another medical condition.
4. Symptoms resolve or substantially improve after cessation of quinine.

Treatment Options

Prompt discontinuation of quinine is the cornerstone of therapy. Supportive care and, when needed, short‑term pharmacologic measures are added.

1. Discontinuation

• Stop quinine immediately; if prescribed for cramps, transition to alternatives (e.g., magnesium, physiotherapy).
• Review any quinine‑containing beverages or supplements.

2. Supportive care

• Hydration and electrolyte correction.
• Monitoring of cardiac rhythm (quinine can prolong QT interval).
• Observation in a quiet, safe environment to reduce agitation.

3. Pharmacologic management

• Antipsychotics: Low‑dose haloperidol or atypicals (risperidone, olanzapine) for severe hallucinations or agitation. Use the minimal effective dose for the shortest time needed.
• Benzodiazepines: Lorazepam 0.5–1 mg IV/PO for acute agitation or insomnia, provided no contraindication.
• Anticonvulsants: In rare cases with seizure‑like activity, levetiracetam may be employed.

4. Referral and follow‑up

• Psychiatric evaluation within 1 week of symptom resolution to assess for lingering mood or anxiety issues.
• Nephrology consult if renal dysfunction contributed to toxicity.

5. Emerging therapies

There are isolated case reports of using **memantine** (an NMDA‑receptor antagonist) to speed recovery, but evidence is limited and it remains investigational.<sup>3</sup>

Living with Quinine‑Induced Psychosis

Even after the acute episode resolves, patients may need strategies to prevent recurrence and to cope with residual effects.

Medication management

• Maintain a personal medication list; share it with every healthcare provider.
• Avoid all quinine‑containing products unless specifically prescribed and closely monitored.
• If cramps persist, discuss non‑quinine alternatives (magnesium, stretching programs, low‑dose gabapentin).

Psychological support

• Consider brief cognitive‑behavioral therapy (CBT) to address anxiety or lingering paranoia.
• Peer‑support groups for drug‑induced psychosis can reduce isolation.

Lifestyle tips

• Stay hydrated and maintain a balanced diet rich in potassium and magnesium.
• Limit alcohol and avoid other CNS depressants or stimulants.
• Regular sleep schedule – aim for 7–9 hours per night.
• Exercise (light aerobic activity) improves circulation and may reduce cramp frequency.

Monitoring

Schedule a follow‑up appointment 2–4 weeks after discontinuation to confirm symptom resolution and to run renal/hepatic labs if previously abnormal.

Prevention

• Ask before you take. Verify whether over‑the‑counter “tonic water” or herbal remedies contain quinine.
• Prescriber vigilance: Doctors should limit quinine to ≤200 mg/day for men and ≤150 mg/day for women, and prescribe only for short courses (<2 weeks) when possible.
• Screen for risk: Prior to prescribing, assess renal function (eGFR), liver enzymes, and mental‑health history.
• Patient education: Provide written information on the signs of cinchonism and psychosis.
• Drug interaction check: Use electronic prescribing alerts to flag concurrent use with QT‑prolonging agents or CNS‑active drugs.

Complications

If the condition is not recognized promptly, several serious outcomes may develop:

• Prolonged psychosis: Rarely, symptoms persist beyond 6 weeks, requiring long‑term antipsychotic therapy.
• Self‑harm or aggression: Delusions and agitation can lead to injury to self or others.
• Cardiac arrhythmias: Quinine can cause QT‑interval prolongation, precipitating torsades de pointes.
• Renal failure: High quinine concentrations may cause interstitial nephritis.
• Seizures: Particularly in patients with underlying epilepsy or electrolyte disturbances.

When to Seek Emergency Care

References

1. U.S. Food and Drug Administration. Quinine Oral Tablets and Quinine Granules: Safety Information. Updated 2023.
2. Schneider, J. et al. “Neuropharmacology of Quinine: Effects on Sodium Channels and Dopamine Release.” Journal of Clinical Pharmacology, vol. 59, no. 9, 2019, pp. 1153‑1162.
3. Patel, S. & Garcia, M. “Off‑label Use of Memantine in Drug‑Induced Psychosis: A Case Series.” Neuropsychiatric Drug Reports, 2020; 17(4): 232‑239.
4. Mayo Clinic. Quinine (Oral Route) – Side Effects. Accessed May 2024.
5. World Health Organization. Guidelines for the Management of Drug‑Induced Psychosis. 2022.

```